Steven Cohen’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.36M Buy
671,505
+576,782
+609% +$6.39M 0.01% 1651
2026
Q2
$2.28M Sell
94,723
-726,456
-88% -$22M ﹤0.01% 2306
2026
Q1
$25M Sell
821,179
-1,018,697
-55% -$27.1M 0.03% 691
2025
Q4
$53.1M Buy
1,839,876
+1,721,285
+1,451% +$22.5M 0.06% 379
2025
Q3
$855K Buy
+118,591
New +$873K ﹤0.01% 1751
2024
Q4
– Sell
-250,204
Closed -$3.81M – 2107
2024
Q3
$3.81M Buy
+250,204
New +$1.24M 0.01% 960

Other funds holding CAPR

Steven Cohen's CAPR Position: Q3 2026 in Review

Steven Cohen increased its Capricor Therapeutics (CAPR) stake by 609% in Q3 2026, buying an estimated $6.39M and bringing the position to 671,505 shares worth $6.36M. The position accounts for 0.01% of the portfolio, ranked #1651.

Steven Cohen first reported a position in CAPR in Q3 2024 and has held it in 6 quarters since. The position peaked at $53.1M in Q4 2025. 156 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Steven Cohen held 671,505 shares of Capricor Therapeutics worth $6.36M as of Q3 2026.
  • Steven Cohen bought 576,782 Capricor Therapeutics shares in Q3 2026, an estimated $6.39M.
  • Capricor Therapeutics made up 0.01% of Steven Cohen's portfolio in Q3 2026, its #1651 holding.
  • Steven Cohen first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Steven Cohen's Capricor Therapeutics position peaked at $53.1M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.